Pharmacokinetic imaging: A noninvasive method for determining drug distribution and action

Clinical Pharmacokinetics

Volumn 41, Issue 8, 2002, Pages 581-602

  Fischman, A J ^a,b   Alpert, N M ^a   Rubin, R H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; ELMUSTINE; ERYTHROMYCIN; FLEROXACIN; FLUCONAZOLE; FLUOROURACIL; LOMEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAMOXIFEN; TEMOZOLOMIDE; TRACER; TROVAFLOXACIN;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG MONITORING; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; RADIOCHEMISTRY; REVIEW; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE;

EID: 0036327828     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241080-00003     Document Type: Review

References (99)

1. Physics in nuclear medicine
2. Positron emission tomography: Principles and quantitation
3. Application of annihilation coincidence detection to transaxial reconstruction tomography
4. Positron emitter-labeled compounds: Priorities and problems
5. Pharmacokinetics of 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography
6. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors
7. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET
8. PET studies of potential chemotherapeutic agents: X. Synthesis of "no-carrier-added" (11C)-HECNU: The hydroxyethyl analog of the chemotherapeutic agent BCNU
9. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer
10. Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man
11. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study
12. In vivo monitoring of drugs using radiotracer techniques
13. Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate
14. Synthesis of 18F-labeled fluconazole and positron emission tomography in rabbits
15. Synthesis and biodistribution of 18F-labeled fleroxacin
16. Synthesis of fluorine-18 lomefloxacin, a fluorinated quinolone antibiotic
17. 18F-labeling and biodistribution of the novel fluoroquinolone antimicrobial agent, trovafloxacin (CP-99,214)
18. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron emission tomography
19. Design and synthesis of a systemically active agent, fluconazole
20. The discovery and profile of fluconazole
21. Discovery of fluconazole, a novel antifungal agent
22. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis
23. Hypothesis on the molecular basis of the antifungal activities of N-substituted imidazoles and triazoles
24. Biochemical targets for antifungal azole-derivative: Hypothesis of the mode of action
25. Defective sterol C5-6 desaturation and azole resistance: A new hypothesis for the mode of action of azole antifungals
26. Toxicological profile and safety evaluation of antifungal azole derivatives
27. Azole antifungal agents: Emphasis on new triazoles
28. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: A randomized trial
29. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
30. Pharmacokinetics and tissue penetration of fluconazole in rabbits
31. Pharmacokinetics and tissue penetration of fluconazole in humans
32. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector
33. Sputum levels of fluconazole in humans
34. Fluconazole penetration into cerebral spinal fluid
35. Steady state parenteral kinetics of fluconazole in man
36. Pharmacokinetics of 18F-labeled fluconazole in normal human subjects studied with positron emission tomography
37. Synthesis and biodistribution of 18F-labeled fleroxacin
38. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with E. coli infections studied with positron emission tomography
39. Pharmacokinetics of [18F]fleroxacin in normal human subjects studied with positron emission tomography
40. Pharmacokinetics of [18F] fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied with positron emission tomography
41. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride
42. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
43. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans: A PET study with [11C]-SCH 23390 and [11C]raclopride
44. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
45. In vivo binding of SCH 39166: A D-1 selective antagonist
46. Imaging dopamine receptors in the human brain by positron tomography
47. 76Br-bromo-spiroperidol: A new tool for quantitative in-vivo imaging of neuroleptic receptors
48. [76Br]Bromolisuride: A new tool for quantitative in vivo imaging of D-2 dopamine receptors
49. Dopamine fiber detection by 11C-CFT and PET in a primate model of Parkinsonism
50. [11C,127I]Altropane: A highly selective ligand for PET imaging of dopamine transporter sites
51. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone
52. Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-Br-LSD
53. Visualization by positron emission tomography of the apparent regional heterogeneity of central type benzodiazepine receptors in the brain of living baboons
54. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography
55. Mu-receptors measured by positron emission tomography are increased in temporal lobe epilepsy
56. Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers
57. 3-[18F]Acetylcyclofoxy: A useful probe for the visualization of opiate receptors in living animals
58. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography
59. Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimide
60. Muscarinic receptor imaging in human brain using [C-11] scopolamine and positron emission tomography
61. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine
62. In vivo investigation of myocardial perfusion, metabolism and receptors by positron emission tomography
63. Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding
64. Quantification of neuroreceptors in the living human brain: II. Inhibition studies of receptor density and affinity
65. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET: A comparison to the equilibrium analysis
66. Kinetic analysis of central [76Br]bromolisuride binding to dopamine D2 receptors studied by PET
67. Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies
68. A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2′-[18F]fluoroethyl)spiperone and dynamic positron emission tomography
69. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
70. Neuroreceptor assay with positron emission tomography: Equilibrium versus dynamic approaches
71. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
72. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
73. Positron emission tomographic analysis of central 5HT2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone
74. Estimation of neocortical serotonin-2-receptor binding potential by single dose 18F-setoperone kinetic PET data analysis
75. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography
76. Graphical evaluation of blood-to-brain transfer constants in multiple-time uptake data
77. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects
78. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study
79. Euphorigenic doses of cocaine reduce [1231] beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts
80. [1231] beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts
81. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy
82. Emerging nuclear magnetic resonance techniques: Health and safety
83. 19F-MRS studies of fluorinated drugs in humans
84. Non-invasive 19F-MRS of 5-fluorouracil in pharmacokinetic and pharmacodynamic studies
85. Imaging of the biodistribution and metabolism of the antineoplastic agent gemcitabine in tumor bearing rats
86. Non-invasive MRS in new anticancer drug development
87. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2- hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia
88. Proton NMR observation of the antineoplastic agent iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC)
89. In vivo detection of ifosfamide by 31P-MRS in rat tumours: Increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas
90. Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer
91. Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats by means of 195Pt NMR
92. Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: A 31P magnetic resonance spectroscopy study
93. Monitoring pharmacokinetics of anticancer drugs: Non-invasive investigation using magnetic resonance spectroscopy
94. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: A study of liver and muscle disposition of fleroxacin in humans
95. In vivo measurement of lithium in humans by nuclear magnetic resonance spectroscopy
96. Measurement of human brain lithium in vivo by MR spectroscopy
97. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration
98. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: A fluorine MRS study